CN1909923B - 基于减毒的兔粘液瘤病毒的单副免疫诱导物 - Google Patents

基于减毒的兔粘液瘤病毒的单副免疫诱导物 Download PDF

Info

Publication number
CN1909923B
CN1909923B CN2005800030491A CN200580003049A CN1909923B CN 1909923 B CN1909923 B CN 1909923B CN 2005800030491 A CN2005800030491 A CN 2005800030491A CN 200580003049 A CN200580003049 A CN 200580003049A CN 1909923 B CN1909923 B CN 1909923B
Authority
CN
China
Prior art keywords
attenuation
virus
myxoma
myxoma virus
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800030491A
Other languages
English (en)
Chinese (zh)
Other versions
CN1909923A (zh
Inventor
安东·迈耶
巴巴拉·迈耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic Research Institute AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Research Institute AS filed Critical Bavarian Nordic Research Institute AS
Publication of CN1909923A publication Critical patent/CN1909923A/zh
Application granted granted Critical
Publication of CN1909923B publication Critical patent/CN1909923B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
CN2005800030491A 2004-01-23 2005-01-21 基于减毒的兔粘液瘤病毒的单副免疫诱导物 Expired - Fee Related CN1909923B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004003572.5 2004-01-23
DE102004003572A DE102004003572A1 (de) 2004-01-23 2004-01-23 Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
PCT/EP2005/000582 WO2005070453A1 (de) 2004-01-23 2005-01-21 Monoparamunitätsinducer basierend auf attenuierten myxomaviren des kaninchens

Publications (2)

Publication Number Publication Date
CN1909923A CN1909923A (zh) 2007-02-07
CN1909923B true CN1909923B (zh) 2012-10-03

Family

ID=34800965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800030491A Expired - Fee Related CN1909923B (zh) 2004-01-23 2005-01-21 基于减毒的兔粘液瘤病毒的单副免疫诱导物

Country Status (15)

Country Link
US (9) US7494799B2 (enExample)
EP (2) EP1711204A1 (enExample)
JP (1) JP4846598B2 (enExample)
KR (2) KR20120076396A (enExample)
CN (1) CN1909923B (enExample)
AU (1) AU2005205912B2 (enExample)
BR (1) BRPI0506489A (enExample)
CA (1) CA2547757A1 (enExample)
DE (1) DE102004003572A1 (enExample)
EA (1) EA009937B1 (enExample)
IL (1) IL176634A (enExample)
NO (1) NO20063605L (enExample)
NZ (1) NZ548189A (enExample)
UA (1) UA91501C2 (enExample)
WO (1) WO2005070453A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
CN102230035B (zh) * 2011-07-06 2013-02-13 中华人民共和国江苏出入境检验检疫局 兔粘液瘤病毒pcr检测试剂盒及其应用
JP6370082B2 (ja) * 2014-04-07 2018-08-08 キヤノン株式会社 情報処理装置、情報処理方法、及びプログラム
JP2017083973A (ja) * 2015-10-23 2017-05-18 富士通株式会社 表示端末装置、表示制御方法および表示制御プログラム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE4405841C1 (de) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
BR0109158A (pt) * 2000-03-14 2003-04-22 Anton Mayr Cepa alterada do vìrus de varìola bovina de ankara (mva)
AU4930001A (en) 2000-04-03 2001-10-15 Univ Pittsburgh Cold-adapted equine influenza viruses
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
AU2003259358A1 (en) 2002-08-30 2004-03-19 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
CA2510309C (en) * 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOSSMAN KAREN ET AL.Myxoma virus M-T7,a secreted homolog of theinterferon-gamma receptor,is a critical virulence factor for thedevelopment of myxomatosisi in European rabbits.VIROLOGY215 1.1996,215(1),17-30.
MOSSMAN KAREN ET AL.Myxoma virus M-T7,a secreted homolog of theinterferon-gamma receptor,is a critical virulence factor for thedevelopment of myxomatosisi in European rabbits.VIROLOGY215 1.1996,215(1),17-30. *
UPTON C ET AL.MYXOMA VIRUS EXPRESSES A SECRETED PROTEINWITH HOMOLOGY TO THE TUMOR NEXROSIS FACTORRECEPTOR GENE FAMILY THAT CONTRIBUTES TOVIRAL VIRULENCE.VIROLOGY184 1.1991,184(1),370-382.
UPTON C ET AL.MYXOMA VIRUS EXPRESSES A SECRETED PROTEINWITH HOMOLOGY TO THE TUMOR NEXROSIS FACTORRECEPTOR GENE FAMILY THAT CONTRIBUTES TOVIRAL VIRULENCE.VIROLOGY184 1.1991,184(1),370-382. *

Also Published As

Publication number Publication date
CA2547757A1 (en) 2005-08-04
US20120070464A1 (en) 2012-03-22
US20100316671A1 (en) 2010-12-16
US7494799B2 (en) 2009-02-24
AU2005205912B2 (en) 2010-07-29
UA91501C2 (ru) 2010-08-10
EP2327420A2 (de) 2011-06-01
EP2327420A3 (de) 2011-07-06
EA009937B1 (ru) 2008-04-28
JP2007534664A (ja) 2007-11-29
WO2005070453A1 (de) 2005-08-04
NZ548189A (en) 2009-02-28
US20120009654A1 (en) 2012-01-12
KR101209141B1 (ko) 2012-12-06
US20110014234A1 (en) 2011-01-20
US20110020908A1 (en) 2011-01-27
DE102004003572A1 (de) 2005-08-18
US20080213307A1 (en) 2008-09-04
HK1095746A1 (en) 2007-05-18
US20120009217A1 (en) 2012-01-12
KR20060129221A (ko) 2006-12-15
CN1909923A (zh) 2007-02-07
AU2005205912A1 (en) 2005-08-04
IL176634A0 (en) 2006-10-31
KR20120076396A (ko) 2012-07-09
IL176634A (en) 2011-03-31
US7939085B2 (en) 2011-05-10
US8039004B2 (en) 2011-10-18
US20080267920A1 (en) 2008-10-30
EA200601361A1 (ru) 2006-12-29
JP4846598B2 (ja) 2011-12-28
US8034356B2 (en) 2011-10-11
WO2005070453A8 (de) 2006-08-03
NO20063605L (no) 2006-08-09
US20070154455A1 (en) 2007-07-05
US8142796B2 (en) 2012-03-27
US7691391B2 (en) 2010-04-06
BRPI0506489A (pt) 2007-02-13
EP1711204A1 (de) 2006-10-18

Similar Documents

Publication Publication Date Title
CN100540051C (zh) 用于接种新生儿的改良的安卡拉痘苗病毒
CN104248757B (zh) 猪伪狂犬病病毒疫苗组合物及其制备方法和应用
US8142796B2 (en) Monoparamunity inducers based on attenuated rabbit myxomaviruses
JP2007534664A5 (enExample)
HK1095746B (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
CN116574698B (zh) 一种tk缺失的牛结节性皮肤病病毒及其应用
MXPA06008005A (en) Monoparaimmunity inducers based on attenuated rabbit myxoma viruses
CN101198339A (zh) 高度减毒的痘病毒株、其生产方法及其作为副免疫诱导物或用于生产载体疫苗的用途
CN108812548A (zh) 布鲁氏菌疫苗免疫牛的方法和用途
CN110923248B (zh) 猪繁殖与呼吸综合征病毒、疫苗及其制备方法和用途
HK1078777B (en) Modified vaccinia virus ankara for the vaccination of neonates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1095746

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1095746

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121003

Termination date: 20140121